Who are the key players in North America Point of Care Molecular Diagnostics Market industry?

The top five players in the North America Point of Care Molecular Diagnostics Market are Abbott Laboratories, Roche Diagnostics, Cepheid (Danaher Corporation), BioMérieux SA, and Hologic Inc. These companies lead the market due to their innovative diagnostic platforms, strong product portfolios, and expanding distribution networks across the region.

Which segment accounted for the largest North America Point of Care Molecular Diagnostics Market share?

The infectious diseases segment holds the largest share in the North America Point of Care Molecular Diagnostics Market. This dominance is attributed to the high prevalence of diseases like influenza, RSV, and HIV, and the growing preference for rapid, accurate tests in clinical and outpatient settings.

What are the factors driving the North America Point of Care Molecular Diagnostics Market?

Key drivers include advancements in molecular diagnostic technologies and the demand for faster clinical decision-making. For example, Cepheid's rapid PCR-based GeneXpert systems have significantly improved detection speed and accuracy, leading to greater adoption in emergency departments and primary care clinics throughout North America.

Which type accounted for the largest North America Point of Care Molecular Diagnostics Market share?

RT-PCR-based tests account for the largest share of the North America Point of Care Molecular Diagnostics Market. These tests are widely preferred due to their high sensitivity, specificity, and established utility in detecting infectious agents, making them the primary choice in both hospital and decentralized settings.

Home Healthcare

North America Point of Care Molecular Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Point of Care Molecular Diagnostics Market
Brand: Bussiness Insights

North America Point of Care Molecular Diagnostics Market: by Type (Infectious Disease, Oncology, Cardiac Markers, Genetic Testing, Blood Screening, Others), Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology, Hematology, Others), Distribution Channels (Hospitals, Diagnostic Centers, Clinics, Pharmacies, Home Care, Others), Technology (PCR, Isothermal Nucleic Acid Amplification, Microarray, Next Generation Sequencing, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20376 | Author: Ankit

RD TOC Segmentation Research Methodology Request For Free Sample

North America Point of Care Molecular Diagnostics Market Analysis (2025-2035)

The North America Point of Care Molecular Diagnostics Market is poised for substantial growth, driven by continuous technological advancements, increasing prevalence of infectious diseases, and growing demand for rapid and accurate diagnostic solutions. With key application areas including infectious diseases, oncology, and genetic testing, the market is increasingly being adopted in various settings such as hospitals, diagnostic centers, and home care. The strong presence of leading global players and rising investment in point-of-care innovation is transforming the healthcare landscape in the region.

Latest Market Dynamics

Key Drivers

Rising prevalence of infectious diseases and chronic conditions, with companies like Abbott Laboratories launching advanced POCT molecular assays in 2025.

In 2025, the North America Point of Care Molecular Diagnostics Market is dominated by the Infectious Disease segment, making up 44% of the market, a trend that stems from heightened demand for rapid diagnostics during infectious outbreaks. Oncology and Genetic Testing follow, representing 19% and 14% of the overall market, respectively. The increasing need for early disease detection and monitoring continues to drive growth in these segments, while Cardiac Markers and Blood Screening collectively account for significant but smaller shares. The robust demand for infectious disease POCT reflects both public health initiatives and the need for timely clinical decision-making.

In 2025, Infectious Diseases continue to drive the majority share in Point of Care Molecular Diagnostics applications, accounting for 46% of the segment due to the persistent threat of viral outbreaks and increasing attention to antimicrobial resistance. Oncology represents 17%, buoyed by innovations in rapid tumor marker detection, while Prenatal Testing holds a noteworthy 13% market share. The ease and speed of point-of-care solutions make them increasingly relevant for Hematology and Endocrinology, though these remain secondary to the leading segments. The diverse clinical utility of POCT amplifies its role in delivering timely and accurate diagnostic information across multiple care settings.

The North America Point of Care Molecular Diagnostics Market is projected to reach a revenue of 4,100 Million USD in 2025, up from 2,100 Million USD in 2020. The market is forecast to grow steadily, culminating at approximately 9,300 Million USD by 2035, reflecting a CAGR of about 8.2% during the forecast period. This robust trajectory is powered by rapid adoption of innovative POCT technologies across healthcare settings, ongoing investments in R&D, and the continuous need for decentralized diagnostic solutions to manage public health threats.

Year-over-Year (YOY) growth in the North America Point of Care Molecular Diagnostics Market peaked at 15% during the 2020-2022 period, largely attributed to pandemic-driven testing demand. Growth rates stabilized to around 8-10% between 2025 and 2030, with a gradual taper to 5% by 2035 as the market reaches maturity and adoption plateaus. The deceleration reflects the transition from rapid, crisis-driven expansion to a steady, innovation-led growth phase with mature penetration in core markets.

The United States dominates the North America Point of Care Molecular Diagnostics Market in 2025 with 64% market share, fueled by its advanced healthcare infrastructure and high R&D spending. Canada follows with 21%, demonstrating strong adoption particularly in urban centers with robust health investments, while Mexico contributes 15%, benefiting from expanding public health initiatives and increased government focus on decentralized healthcare access. The regional dynamics underscore differing paces of technological uptake but confirm a continent-wide shift towards rapid point-of-care diagnostics.

Abbott Laboratories leads the North America Point of Care Molecular Diagnostics Market with a 22% share in 2025, owing to its broad POCT portfolio and market reach. Roche Diagnostics and Danaher Corporation follow, with shares of 17% and 13% respectively. Other prominent players include BioMérieux, Thermo Fisher Scientific, and Quidel Corporation. The competitive landscape is characterized by ongoing innovation and a race to deliver more sensitive, accessible, and integrated diagnostic solutions across critical care environments.

In 2025, hospitals constitute the largest buyer segment in North America for point-of-care molecular diagnostics, accounting for 41% of purchases driven by high testing volumes and comprehensive care mandates. Diagnostic centers and clinics collectively represent 33% of market share, reflecting their critical role in decentralized healthcare delivery. The emergence of home care and retail pharmacies also signals a growing shift towards patient-centric, out-of-hospital diagnostic testing, facilitated by user-friendly POCT technologies.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	4100
Regions	United States, Canada, Mexico
Segments	By Type: Infectious Disease, Oncology, Cardiac Markers, Genetic Testing, Blood Screening, Others; By Application: Infectious Diseases, Oncology, Prenatal Testing, Endocrinology, Hematology, Others; By Technology: PCR, Isothermal Nucleic Acid Amplification, Microarray, NGS, Immunoassay, Others; By Distribution Channel: Hospitals, Diagnostic Centers, Clinics, Pharmacies, Home Care, Others; By Organization Size: Small, Medium, Large
Players	Abbott Laboratories, Roche Diagnostics, Danaher Corporation, BioMérieux, Quidel Corporation, Siemens Healthineers, Thermo Fisher Scientific, Becton Dickinson and Company, Cepheid, Hologic Inc., Luminex Corporation, Qiagen N.V., GenMark Diagnostics, Mesa Biotech, Accula Inc.

June 2024: Abbott Laboratories launched Alinity m Resp-4-Plex assay, a new rapid POCT panel for detection of SARS-CoV-2, influenza A/B, and RSV.
July 2024: Roche Diagnostics received FDA clearance for cobas Liat Multiplex CT/NG test, further expanding its US POCT portfolio.
August 2024: Thermo Fisher Scientific introduced a portable QuantStudio qPCR device aimed at home and remote clinical use.
September 2024: Danaher Corporation announced partnerships with US health networks to pilot low-cost syndromic POCT for rural clinics.
October 2024: BioMérieux unveiled BioFire BCID3, a multiplex molecular panel approved for rapid bloodstream infection diagnosis at the point of care.

About the Author

Ankit

Senior Research Consultant

Ankit is a Senior Research Consultant specializing in market research, industry analysis, and business consulting across Healthcare. Ankit brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Ankit has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America Point of Care Molecular Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Point of Care Molecular Diagnostics Market Analysis (2025-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share by Type, 2025

Market Share by Applications, 2025

Market Revenue (USD Million), 2020-2035

Market YOY Growth (%), 2020-2035

Market Share by Region, 2025

Market Share by Key Players, 2025

Market Share by Buyer Type, 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports